Arbutus Biopharma Corp Stock Filter Stocks by Fundamentals
ABUS Stock | USD 2.58 0.02 0.77% |
Arbutus Biopharma Corp fundamentals help investors to digest information that contributes to Arbutus Biopharma's financial success or failures. It also enables traders to predict the movement of Arbutus Stock. The fundamental analysis module provides a way to measure Arbutus Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Arbutus Biopharma stock.
Cash Per Share is likely to drop to 0.72 in 2024. Arbutus | Cash per Share |
Arbutus Cash per Share Analysis
Current Arbutus Biopharma Cash per Share | 0.72 |
Most of Arbutus Biopharma's fundamental indicators, such as Cash per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arbutus Biopharma Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Arbutus Cash per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Arbutus Biopharma is extremely important. It helps to project a fair market value of Arbutus Stock properly, considering its historical fundamentals such as Cash per Share. Since Arbutus Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arbutus Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arbutus Biopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Arbutus Cash per Share Historical Pattern
Today, most investors in Arbutus Biopharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Arbutus Biopharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's cash per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Arbutus Biopharma cash per share as a starting point in their analysis.
Arbutus Biopharma Cash per Share |
Timeline |
Competition |
Arbutus Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Did you try this?
Run Stock Screener Now
Stock ScreenerFind equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
All Next | Launch Module |
Arbutus Fundamentals
Return On Equity | -0.6 | ||||
Return On Asset | -0.29 | ||||
Operating Margin | (9.57) % | ||||
Current Valuation | 340.65 M | ||||
Shares Outstanding | 179.49 M | ||||
Shares Owned By Insiders | 23.43 % | ||||
Shares Owned By Institutions | 44.06 % | ||||
Number Of Shares Shorted | 4.13 M | ||||
Price To Earning | (1.16) X | ||||
Price To Book | 4.38 X | ||||
Price To Sales | 25.64 X | ||||
Revenue | 18.14 M | ||||
Gross Profit | (45.39 M) | ||||
EBITDA | (76.63 M) | ||||
Net Income | (72.85 M) | ||||
Cash And Equivalents | 150.2 M | ||||
Cash Per Share | 1.00 X | ||||
Total Debt | 8.72 M | ||||
Debt To Equity | 0.02 % | ||||
Current Ratio | 5.29 X | ||||
Book Value Per Share | 0.62 X | ||||
Cash Flow From Operations | (85.94 M) | ||||
Short Ratio | 4.77 X | ||||
Earnings Per Share | (0.44) X | ||||
Target Price | 4.4 | ||||
Number Of Employees | 73 | ||||
Beta | 2.04 | ||||
Market Capitalization | 465.05 M | ||||
Total Asset | 144.4 M | ||||
Retained Earnings | (1.28 B) | ||||
Working Capital | 109.54 M | ||||
Current Asset | 183.88 M | ||||
Current Liabilities | 10.58 M | ||||
Z Score | 18.9 | ||||
Net Asset | 144.4 M |
About Arbutus Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arbutus Biopharma Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arbutus Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arbutus Biopharma Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Last Reported | Projected for 2024 | ||
Cash Per Share | 0.76 | 0.72 |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Arbutus Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Arbutus Biopharma's short interest history, or implied volatility extrapolated from Arbutus Biopharma options trading.
Pair Trading with Arbutus Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arbutus Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arbutus Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against Arbutus Stock
0.57 | VALN | Valneva SE ADR Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Arbutus Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arbutus Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arbutus Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arbutus Biopharma Corp to buy it.
The correlation of Arbutus Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arbutus Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arbutus Biopharma Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arbutus Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Arbutus Biopharma Piotroski F Score and Arbutus Biopharma Altman Z Score analysis. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Complementary Tools for Arbutus Stock analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Stocks Directory Find actively traded stocks across global markets | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
Is Arbutus Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arbutus Biopharma. If investors know Arbutus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arbutus Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.44) | Revenue Per Share 0.109 | Quarterly Revenue Growth (0.66) | Return On Assets (0.29) | Return On Equity (0.60) |
The market value of Arbutus Biopharma Corp is measured differently than its book value, which is the value of Arbutus that is recorded on the company's balance sheet. Investors also form their own opinion of Arbutus Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Arbutus Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arbutus Biopharma's market value can be influenced by many factors that don't directly affect Arbutus Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arbutus Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Arbutus Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arbutus Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.